A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17).
E J KangY YangS LeeY J KimS M LimM-J AhnY J ChoiY LeeT M KimI KimH K AhnH-C JeungS I LeeS Y OhW K BaeH RyuK H ParkK H Lee
Published in: ESMO open (2024)
Tepotinib demonstrated consistent antitumor activity in patients with METex14, and promising antitumor activity in various cancers with MET amplification. Detection of MET dysregulation by plasma NGS may predict the response to tepotinib.